BD Diagnostics' Deal with Lonza Pushes BD Max Platform into Pharma QC Market
October 28, 2010
BD Diagnostics' Deal with Lonza Pushes BD Max Platform into Pharma QC Market
BD Diagnostics and Switzerland's Lonza have inked an agreement to develop and commercialize Lonza's microCompass molecular assays on the BD Max system for pharmaceutical quality-control testing.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Lonza to Distribute Roche's Mycoplasma Detection Kits
April 14, 2011 / PCR Insider - Dx Focus: Luminex, BD Diagnostics, Diagenode, BioFire Diagnostics, IMDx
April 18, 2013 / PCR Insider - BD Diagnostics Division Sees 5 Percent Growth in FY Q1, but MDx Not Yet a Major Driver
February 7, 2013 / PCR Insider - Becton Dickinson Looks to Serve Several Market Segments as it Builds Out Molecular Testing Pipeline
January 3, 2013 / PCR Insider - BD Diagnostics, Diagenode Launch BD Max Flu A/B Test in Europe
November 8, 2012 / PCR Insider